Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Dubravka, Sertić"'
Autor:
Zrinka Sertić, Marko Lucijanić, Sandra Bašić-Kinda, Ranka Serventi Seiwerth, Vlatka Periša, Dubravka Sertić, Božena Coha, Dražen Pulanić, Zinaida Perić, Lana Desnica, Mirta Mikulić, Marijo Vodanović, Ivo Radman-Livaja, Dragana Šegulja, Dunja Rogić, Toni Valković, Igor Aurer, Nadira Duraković
Publikováno v:
Biomedicines, Vol 10, Iss 11, p 2892 (2022)
Disease- and treatment-mediated immunodeficiency might render SARS-CoV-2 vaccines less effective in patients with hematologic diseases. We performed a prospective non-interventional study to evaluate humoral response after one and two doses of mRNA-1
Externí odkaz:
https://doaj.org/article/302bd8409cfa4283acb5a7c1a229e798
Publikováno v:
Southeastern European Medical Journal, Vol 2, Iss 1, Pp 1-11 (2018)
Introduction: Horne and Östberg Morningness-Eveningness Questionnaire (MEQ) is a questionnaire widely used to assess the circadian typology. The aim of this study was to translate the MEQ from English into Croatian. Methods: The translation pr
Externí odkaz:
https://doaj.org/article/b1ba55dfeeec4979b7144679cc0af834
Autor:
Ranka Serventi Seiwerth, Martina Moric Peric, Alen Ostojić, Vlatka Periša, Pavle Rončević, Ines Bojanić, Nadira Duraković, Igor Aurer, Goran Rinčić, Sandra Bašić-Kinda, Ivana Budisavljević, Marijo Vodanović, Ivo Radman, Silva Zupančić-Šalek, Vedrana Gačić, Dominik Lozić, Dubravka Sertić, Ivan Zekanović
Publikováno v:
Liječnički vjesnik. 140:303-306
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::652a531221396fda79b632fff800675d
https://doi.org/10.26800/lv-140-11-12-40
https://doi.org/10.26800/lv-140-11-12-40
Autor:
Nadira Duraković, Bozena Coha, Dunja Rogić, Vlatka Periša, Ranka Serventi Seiwerth, Drazen Pulanic, Sandra Bašić-Kinda, Dragana Šegulja, Zrinka Sertić, Marko Lucijanic, Igor Aurer, Dubravka Sertić, Toni Valković
Publikováno v:
Blood
Background Patients with hematologic malignancy have a higher risk of death from COVID-19 compared to the general population. A blunted immune response from both the underlying disease and applied treatment may contribute to development of more sever
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8b515936478836a1eb4772718c9ddd3
https://doi.org/10.1182/blood-2021-153573
https://doi.org/10.1182/blood-2021-153573
Background: Maintenance therapy after autologous hematopoietic stem cell transplantation (AHSCT) in multiple myeloma (MM) patients was a matter of debate until recently, when lenalidomide in this setting proved to increase overall survival (OS). Befo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::319086720935ea698d956832c631dbd1
https://www.bib.irb.hr/1260394
https://www.bib.irb.hr/1260394
Autor:
Igor Aurer, Radovan Vrhovac, Dubravka Sertić, Drazen Pulanic, Sandra Bašić-Kinda, Marijo Vodanović, Ivo Radman, A. Boban, Renata Zadro, Silva Zupančić-Šalek, Boris Labar, Nadira Duraković, Margareta Radić Antolic, Ivana Horvat, Pavle Rončević, Ranka Serventi-Seiwerth, Damir Nemet
Introduction: Thrombosis is the most common complication in Philadelphia chromosome negative (Ph-) myeloproliferative neoplasms patients. ----- Patients and methods: In a cohort of 258 Ph- myeloproliferative neoplasm patients, the difference between
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::452bcd4f96e85161d71ea48f41d60a81
https://www.bib.irb.hr/979460
https://www.bib.irb.hr/979460
Autor:
Ranka Serventi-Seiwerth, A. Boban, Drazen Pulanic, Nadira Duraković, Dubravka Sertić, Josip Batinić, S. Zupancic-Salek, Pavle Rončević, Mirta Mikulić, R. Vrhovac, Zinaida Peric, I. Aurer, A. Ostojic, I. Radman, S. Bašić-Kinda, Dino Dujmović
Publikováno v:
HemaSphere. 3:771
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d61b1f6b4e6d99f3090540eb5fd93612
https://doi.org/10.1097/01.hs9.0000564920.99794.0a
https://doi.org/10.1097/01.hs9.0000564920.99794.0a
Autor:
B. Dreta, I. Zekanovic, P. Roncevic, J. Petrovic, I. Bojanic, J. Batinic, Dubravka Sertić, I. Radman, T. Valkovic, D. Lozic, I. Aurer, G. Rincic, Nadira Duraković, V. Periša, S. Bašić-Kinda
Publikováno v:
HemaSphere. 3:1037
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73642f20aefefb026f07a787c95c2eaa
https://doi.org/10.1097/01.hs9.0000567772.32395.cb
https://doi.org/10.1097/01.hs9.0000567772.32395.cb
Autor:
Drago Batinić, Ines Bojanić, D. Pulanić, K. Gjadrov-Kuveždić, Nadira Duraković, Barbara Dreta, Pavle Rončević, R. Serventi Seiwerth, Klara Dubravčić, Alen Ostojić, Josip Batinić, I. Aurer, Sandra Bašić-Kinda, Ivana Ilić, I. Hude, Dubravka Sertić, Damir Nemet
Publikováno v:
HemaSphere. 3:976
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7130618a23867364d19e24b572e875ab
https://doi.org/10.1097/01.hs9.0000567180.98783.1e
https://doi.org/10.1097/01.hs9.0000567180.98783.1e
Autor:
Nikolina Matić, Ranka Serventi-Seiwerth, Damir Nemet, Pavle Rončević, Zinaida Peric, Dubravka Sertić, Ivo Radman, Alen Ostojić, Paula Granic, Sandra Bašić-Kinda, Renata Zadro
INTRODUCTION: For over a decade, imatinib has been the first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML). Doubts on the bioequivalence and bioavailability of emerging generic compounds have been expressed. Adequa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ff19c390d49b311b1d0b3eec5b72990
https://doi.org/10.1016/j.clml.2016.04.003
https://doi.org/10.1016/j.clml.2016.04.003